Industry Report
Compass Brand Performance Tracker Q1 2026 - Novel Therapy Launches
Insights from Veeva Projected Prescription and Procedure Data: Commercial Momentum and Market Adoption
Powered by projected prescription and procedure data in Compass Prescriber and National, this report shows estimated unique patient starts and healthcare providers (HCPs) across recent novel therapy launches.
Compass includes non-retail channels, offering a more complete picture of commercial momentum. The performance metrics below represent cumulative, launch-to-date totals.
| Brand | Manufacturer | Disease Area | Cumulative Patient Starts |
Cumulative HCP Counts |
|---|---|---|---|---|
| Adstiladrin | Ferring Pharma | Bladder Cancer | 3,165 | 787 |
| Anktiva | Altor BioScience | Bladder Cancer | 788 | 289 |
| Attruby | BridgeBio Pharma | Cardiomyopathy | 5,370 | 977 |
| Cobenfy | Bristol Myers Squibb | Schizophrenia | 32,794 | 12,599 |
| Livdelzi | Gilead Sciences | Liver Cirrhosis | 5,106 | 1,504 |
| Miplyffa | Zevra Therapeutics | Niemann Pick Disease | 122 | 37 |
| Niktimvo | Incyte | Graft Versus Host Disease | 1,491 | 603 |
| Revuforj | Syndax Pharma | Acute Leukemias (ALL, AMML, AML) |
881 | 481 |
| Rezdiffra | Madrigal Pharma | Liver Fibrosis | 36,541 | 4,725 |
| Wainua | AstraZeneca | Amyloidosis | 1,108 | 287 |
| Brand | Manufacturer | Disease Area | Cumulative Patient Starts | Cumulative HCP Counts |
|---|---|---|---|---|
| Adstiladrin | Ferring Pharma | Bladder Cancer | 3,165 | 787 |
| Anktiva | Altor BioScience | Bladder Cancer | 788 | 289 |
| Attruby | BridgeBio Pharma | Cardiomyopathy | 5,370 | 977 |
| Cobenfy | Bristol Myers Squibb | Schizophrenia | 32,794 | 12,599 |
| Livdelzi | Gilead Sciences | Liver Cirrhosis | 5,106 | 1,504 |
| Miplyffa | Zevra Therapeutics | Niemann Pick Disease | 122 | 37 |
| Niktimvo | Incyte | Graft Versus Host Disease | 1,491 | 603 |
| Revuforj | Syndax Pharma | Acute Leukemias (ALL, AMML, AML) | 881 | 481 |
| Rezdiffra | Madrigal Pharma | Liver Fibrosis | 36,541 | 4,725 |
| Wainua | AstraZeneca | Amyloidosis | 1,108 | 287 |
Additional recent launches also available:
- Bildyos (Organon Pharma)
- Bilprevda (Organon Pharma)
- Cardamyst (Milestone Pharma)
- Inlexzo (Janssen Pharma)
- Inluriyo (Eli Lilly and Company)
- Itvisma (Novartis)
- Javadin (Azurity)
- Keytruda Qlex (Merck)
- Kirsty (Biocon Biologics)
- Kyxata (Avyxa Pharma)
- Myqorzo (Cytokinetics)
- Palsonify (Crinetics Pharma)
- Rybrevant Faspro (Janssen)
- Starjemza (Hikma Pharma)
- Tyzavan (Hikma Pharma)
- Voyxact (Otsuka)
- Yartemlea (Omeros)
To learn more about these launch brands or explore custom market analysis, contact anthony.billinger@veeva.com.